nach oben

04.03.2024 | Psychiatry and Preclinical Psychiatric Studies - Short communication

Genetic mouse models in opioid research: current status and future directions

verfasst von: Monserrat Avila-Zozaya, Venetia Zachariou

Erschienen in: Journal of Neural Transmission

Einloggen, um Zugang zu erhalten

Abstract

Synthetic and semi-synthetic opioids are prescribed for the management of severe pain conditions, but their long-term use is often leading to physical dependence and addiction disorders. Understanding the complex neurobiology of the opioid system in preclinical models will be essential for the development of safe and efficacious analgesics. With rising numbers of synthetic opioid users and overdose cases, a better understanding of the neuroanatomical and cellular pathways associated with physical dependence and addiction is expected to guide treatment approaches for opioid use disorders. In this commentary, we highlight the importance of advanced genetic mouse models for studying the regional effects of opioid receptors, and we discuss the need of genetic mouse models for the investigation of the regional, circuit and cell compartment-specific role of intracellular mediators of opioid actions.

Bailey CP, Oldfield S, Llorente J, Caunt CJ, Teschemacher AG, Roberts L, McArdle CA, Smith FL, Dewey WL, Kelly E, Henderson G (2009) Involvement of PKC alpha and G-protein-coupled receptor kinase 2 in agonist-selective desensitization of mu-opioid receptors in mature brain neurons. Br J Pharmacol 158:157–164CrossRefPubMedPubMedCentral

Ben Hamida S, Boulos LJ, McNicholas M, Charbogne P, Kieffer BL (2019) Mu opioid receptors in GABAergic neurons of the forebrain promote alcohol reward and drinking. Addict Biol 24:28–39CrossRefPubMed

Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG (2000) Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 408:720–723CrossRefPubMed

Bohn LM, Gainetdinov RR, Sotnikova TD, Medvedev IO, Lefkowitz RJ, Dykstra LA, Caron MG (2003) Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. J Neurosci 23:10265–10273CrossRefPubMedPubMedCentral

Boulos LJ, Ben Hamida S, Bailly J, Maitra M, Ehrlich AT, Gaveriaux-Ruff C, Darcq E, Kieffer BL (2020) Mu opioid receptors in the medial habenula contribute to naloxone aversion. Neuropsychopharmacology 45:247–255CrossRefPubMed

Charbogne P, Kieffer BL, Befort K (2014) 15 years of genetic approaches in vivo for addiction research: opioid receptor and peptide gene knockout in mouse models of drug abuse. Neuropharmacol 76 Pt B :204–217

Charlton JJ, Allen PB, Psifogeorgou K, Chakravarty S, Gomes I, Neve RL, Devi LA, Greengard P, Nestler EJ, Zachariou V (2008) Multiple actions of spinophilin regulate mu opioid receptor function. Neuron 58:238–247CrossRefPubMedPubMedCentral

Darcq E, Kieffer BL (2018) Opioid receptors: drivers to addiction? Nat Rev Neurosci 19:499–514CrossRefPubMed

Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F, Befort K, Gaveriaux-Ruff C, Dierich A, LeMeur M, Valverde O, Maldonado R, Kieffer BL (2000) Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25:195–200CrossRefPubMed

Gaspari S, Papachatzaki MM, Koo JW, Carr FB, Tsimpanouli M-E, Stergiou E, Bagot RC, Ferguson D, Mouzon E, Chakravarty S, Deisseroth K, Lobo MK, Zachariou V (2014) Nucleus Accumbens-Specific interventions in RGS9-2 activity modulate responses to Morphine. Neuropsychopharmacology 39:1968–1977CrossRefPubMedPubMedCentral

Gaspari S, Cogliani V, Manouras L, Anderson EM, Mitsi V, Avrampou K, Carr FB, Zachariou V (2017) RGS9-2 modulates responses to Oxycodone in Pain-Free and Chronic Pain States. Neuropsychopharmacology 42:1548–1556CrossRefPubMedPubMedCentral

Gaspari S, Purushothaman I, Cogliani V, Sakloth F, Neve RL, Howland D, Ring RH, Ross EM, Shen L, Zachariou V (2018) Suppression of RGSz1 function optimizes the actions of opioid analgesics by mechanisms that involve the Wnt/beta-catenin pathway. Proc Natl Acad Sci U S A 115:E2085–E2094CrossRefPubMedPubMedCentral

Gluck L, Loktev A, Mouledous L, Mollereau C, Law PY, Schulz S (2014) Loss of morphine reward and dependence in mice lacking G protein-coupled receptor kinase 5. Biol Psychiatry 76:767–774CrossRefPubMedPubMedCentral

Han MH, Renthal W, Ring RH, Rahman Z, Psifogeorgou K, Howland D, Birnbaum S, Young K, Neve R, Nestler EJ, Zachariou V (2010) Brain region specific actions of regulator of G protein signaling 4 oppose morphine reward and dependence but promote analgesia. Biol Psychiatry 67:761–769CrossRefPubMed

Jullie D, Gondin AB, von Zastrow M, Canals M (2020) Opioid pharmacology under the microscope. Mol Pharmacol 98:425–432CrossRefPubMedPubMedCentral

Kieffer BL (1999) Opioids: first lessons from knockout mice. Trends Pharmacol Sci 20:19–26CrossRefPubMed

Kieffer BL, Gaveriaux-Ruff C (2002) Exploring the opioid system by gene knockout. Prog Neurobiol 66:285–306CrossRefPubMed

Lalanne L, Ayranci G, Kieffer BL, Lutz PE (2014) The kappa opioid receptor: from addiction to depression, and back. Front Psychiatry 5:170CrossRefPubMedPubMedCentral

Lamberts JT, Smith CE, Li MH, Ingram SL, Neubig RR, Traynor JR (2013) Differential control of opioid antinociception to thermal stimuli in a knock-in mouse expressing regulator of G-protein signaling-insensitive galphao protein. J Neurosci 33:4369–4377CrossRefPubMedPubMedCentral

Lamberts JT, Rosenthal LD, Jutkiewicz EM, Traynor JR (2018) Role of the guanine nucleotide binding protein, Galpha(o,) in the development of morphine tolerance and dependence. Psychopharmacology 235:71–82CrossRefPubMed

Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P, Tzavara E, Hanoune J, Roques BP, Kieffer BL (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383:819–823CrossRefPubMed

Murlanova K, Jouroukhin Y, Novototskaya-Vlasova K, Huseynov S, Pletnikova O, Morales MJ, Guan Y, Kamiya A, Bergles DE, Dietz DM, Pletnikov MV (2023) Loss of Astrocytic micro Opioid Receptors Exacerbates Aversion Associated with Morphine Withdrawal in Mice: Role of Mitochondrial Respiration. Cells 12

Raehal KM, Walker JK, Bohn LM (2005) Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther 314:1195–1201CrossRefPubMed

Sakloth F, Polizu C, Bertherat F, Zachariou V (2020) Regulators of G Protein Signaling in Analgesia and Addiction. Mol Pharmacol 98:739–750CrossRefPubMedPubMedCentral

Sakloth F, Sanchez-Reyes OB, Ruiz A, Nicolais A, Serafini RA, Pryce KD, Bertherat F, Torres-Berrio A, Gomes I, Devi LA, Wacker D, Zachariou V (2023) A Regional and Projection-Specific Role of RGSz1 in the Ventrolateral Periaqueductal Grey in the modulation of morphine reward. Mol Pharmacol 103:1–8CrossRefPubMedPubMedCentral

Simonin F, Valverde O, Smadja C, Slowe S, Kitchen I, Dierich A, Le Meur M, Roques BP, Maldonado R, Kieffer BL (1998) Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J 17:886–897CrossRefPubMedPubMedCentral

Sutton LP, Khalatyan N, Savas JN, Martemyanov KA (2021) Striatal RGS7 Regulates Depression-Related Behaviors and Stress-Induced Reinstatement of Cocaine Conditioned Place Preference. eNeuro 8

Talbot JN, Roman DL, Clark MJ, Roof RA, Tesmer JJ, Neubig RR, Traynor JR (2010) Differential modulation of mu-opioid receptor signaling to adenylyl cyclase by regulators of G protein signaling proteins 4 or 8 and 7 in permeabilised C6 cells is Galpha subtype dependent. J Neurochem 112:1026–1034CrossRefPubMed

Terman GW, Jin W, Cheong YP, Lowe J, Caron MG, Lefkowitz RJ, Chavkin C (2004) G-protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal. Br J Pharmacol 141:55–64CrossRefPubMed

Varga AG, Reid BT, Kieffer BL, Levitt ES (2020) Differential impact of two critical respiratory centres in opioid-induced respiratory depression in awake mice. J Physiol 598:189–205CrossRefPubMed

Wang Q, Traynor JR (2011) Opioid-induced down-regulation of RGS4: role of ubiquitination and implications for receptor cross-talk. J Biol Chem 286:7854–7864CrossRefPubMedPubMedCentral

Whistler JL, von Zastrow M (1998) Morphine-activated opioid receptors elude desensitization by beta-arrestin. Proc Natl Acad Sci U S A 95:9914–9919CrossRefPubMedPubMedCentral

Zachariou V, Georgescu D, Sanchez N, Rahman Z, DiLeone R, Berton O, Neve RL, Sim-Selley LJ, Selley DE, Gold SJ, Nestler EJ (2003) Essential role for RGS9 in opiate action. Proc Natl Acad Sci U S A 100:13656–13661CrossRefPubMedPubMedCentral

Titel: Genetic mouse models in opioid research: current status and future directions
verfasst von: Monserrat Avila-Zozaya
Venetia Zachariou
Publikationsdatum: 04.03.2024
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-024-02762-6

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen